Cited 16 times in
Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조호진 | - |
dc.contributor.author | 김경식 | - |
dc.contributor.author | 최기홍 | - |
dc.contributor.author | 윤미진 | - |
dc.contributor.author | 황상현 | - |
dc.date.accessioned | 2020-07-16T16:47:53Z | - |
dc.date.available | 2020-07-16T16:47:53Z | - |
dc.date.issued | 2017-01 | - |
dc.identifier.issn | 0363-9762 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/178318 | - |
dc.description.abstract | Purpose: The aim of this article was to evaluate the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on preoperative F-FDG PET/CT for predicting intrahepatic recurrence-free survival (IHRFS), extrahepatic metastasis-free survival (EHMFS), and overall survival (OS) in patients with very early/early hepatocellular carcinoma (HCC). Patients and methods: We retrospectively enrolled 132 patients with very early/early HCC who underwent F-FDG PET/CT followed by surgery. The maximum tumor SUV-to-mean normal liver SUV ratio, MTV, and TLG were measured for each patient. Prognostic significances of PET/CT parameters and clinicopathologic factors for IHRFS, EHMFS, and OS were evaluated. Cumulative IHRFS, EHMFS, and OS were calculated using the Kaplan-Meier method. Results: Thirty-three (25%) and 21 (15.9%) of 132 patients experienced intrahepatic and extrahepatic recurrence, respectively, during a median follow-up period of 38.1 months. In multivariate analysis, none of the factors were significant for IHRFS. Metabolic tumor volume and TLG were only significant factors for EHMFS and OS (P < 0.05). The 5-year EHMFS rates were 94.8% in patients with low MTV and TLG, and 62.1% and 63.2% in patients with high MTV and TLG, respectively (P < 0.001). The 5-year OS rates were 92.6% and 92.4% in patients with low MTV and TLG, and 63.3% and 64.3% in patients with high MTV and TLG, respectively (P < 0.001). Conclusions: Metabolic tumor volume and TLG on preoperative PET/CT were independent prognostic factors for EHMFS and OS but not IHRFS in patients with very early/early HCC. Therefore, patients with high MTV or TLG should be closely observed for extrahepatic metastasis using systemic evaluations. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Lippincott | - |
dc.relation.isPartOf | CLINICAL NUCLEAR MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Carcinoma, Hepatocellular / diagnostic imaging* | - |
dc.subject.MESH | Carcinoma, Hepatocellular / metabolism | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorodeoxyglucose F18* / metabolism | - |
dc.subject.MESH | Glycolysis* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Neoplasms / diagnostic imaging* | - |
dc.subject.MESH | Liver Neoplasms / metabolism | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Positron Emission Tomography Computed Tomography* | - |
dc.subject.MESH | Predictive Value of Tests | - |
dc.subject.MESH | Radiopharmaceuticals* | - |
dc.title | Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Nuclear Medicine (핵의학교실) | - |
dc.contributor.googleauthor | Sang Hyun Hwang | - |
dc.contributor.googleauthor | Jeong Won Lee | - |
dc.contributor.googleauthor | Ho Jin Cho | - |
dc.contributor.googleauthor | Kyung Sik Kim | - |
dc.contributor.googleauthor | Gi Hong Choi | - |
dc.contributor.googleauthor | Mijin Yun | - |
dc.identifier.doi | 10.1097/RLU.0000000000001449 | - |
dc.contributor.localId | A03941 | - |
dc.contributor.localId | A00299 | - |
dc.contributor.localId | A04046 | - |
dc.contributor.localId | A02550 | - |
dc.relation.journalcode | J00595 | - |
dc.identifier.eissn | 1536-0229 | - |
dc.identifier.pmid | 27775949 | - |
dc.identifier.url | https://journals.lww.com/nuclearmed/Fulltext/2017/01000/Prognostic_Value_of_Metabolic_Tumor_Volume_and.6.aspx | - |
dc.contributor.alternativeName | Cho, Ho Jin | - |
dc.contributor.affiliatedAuthor | 조호진 | - |
dc.contributor.affiliatedAuthor | 김경식 | - |
dc.contributor.affiliatedAuthor | 최기홍 | - |
dc.contributor.affiliatedAuthor | 윤미진 | - |
dc.citation.volume | 42 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 34 | - |
dc.citation.endPage | 39 | - |
dc.identifier.bibliographicCitation | CLINICAL NUCLEAR MEDICINE, Vol.42(1) : 34-39, 2017-01 | - |
dc.identifier.rimsid | 64718 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.